Literature DB >> 21114524

Safety of agalsidase alfa in patients with Fabry disease under 7 years.

U Ramaswami1, R Parini, C Kampmann, M Beck.   

Abstract

AIM: To evaluate the safety and explore the efficacy of enzyme replacement therapy (ERT) for Fabry disease with agalsidase alfa in young children enrolled in the Fabry Outcome Survey (FOS).
METHODS: This retrospective chart review identified eight children (mean age= 5.0±1.6 [mean ±SD]) in FOS who began treatment with agalsidase alfa (0.2 mg/kg, i.v., every other week) when <7 years old. Vital signs and adverse events were monitored throughout the study period. Glomerular filtration rate (GFR) was estimated, and left ventricular mass indexed to height(2.7) (LVMi) was assessed with echocardiography. Patients received 1.2-6.7 years of treatment (mean=4.2 years).
RESULTS: Infusion reactions occurred in three patients and were of mild or moderate severity. IgG antibodies to agalsidase alfa were found in one patient who experienced two mild and one moderate infusion reactions. Mean GFR was within the normal range at baseline and remained normal. LVMi was above the 75th percentile of age-matched children in 5 of 6 patients evaluated at baseline. Only two patients exceeded this threshold at their last assessment.
CONCLUSION: Long-term observation will be needed to determine whether early initiation of ERT will prevent major organ dysfunction in these patients.
© 2011 The Author(s)/Acta Paediatrica © 2011 Foundation Acta Paediatrica.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21114524     DOI: 10.1111/j.1651-2227.2010.02101.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  6 in total

Review 1.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.

Authors:  Saskia M Rombach; Bouwien E Smid; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  J Inherit Metab Dis       Date:  2014-02-04       Impact factor: 4.982

Review 2.  Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.

Authors:  Michael Beck; Uma Ramaswami; Elizabeth Hernberg-Ståhl; Derralynn A Hughes; Christoph Kampmann; Atul B Mehta; Kathleen Nicholls; Dau-Ming Niu; Guillem Pintos-Morell; Ricardo Reisin; Michael L West; Jörn Schenk; Christina Anagnostopoulou; Jaco Botha; Roberto Giugliani
Journal:  Orphanet J Rare Dis       Date:  2022-06-20       Impact factor: 4.303

Review 3.  Fabry disease in infancy and early childhood: a systematic literature review.

Authors:  Dawn A Laney; Dawn S Peck; Andrea M Atherton; Linda P Manwaring; Katherine M Christensen; Suma P Shankar; Dorothy K Grange; William R Wilcox; Robert J Hopkin
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

Review 4.  Update on role of agalsidase alfa in management of Fabry disease.

Authors:  Uma Ramaswami
Journal:  Drug Des Devel Ther       Date:  2011-03-14       Impact factor: 4.162

Review 5.  Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN).

Authors:  Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

6.  Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.

Authors:  Marieke Biegstraaten; Reynir Arngrímsson; Frederic Barbey; Lut Boks; Franco Cecchi; Patrick B Deegan; Ulla Feldt-Rasmussen; Tarekegn Geberhiwot; Dominique P Germain; Chris Hendriksz; Derralynn A Hughes; Ilkka Kantola; Nesrin Karabul; Christine Lavery; Gabor E Linthorst; Atul Mehta; Erica van de Mheen; João P Oliveira; Rossella Parini; Uma Ramaswami; Michael Rudnicki; Andreas Serra; Claudia Sommer; Gere Sunder-Plassmann; Einar Svarstad; Annelies Sweeb; Wim Terryn; Anna Tylki-Szymanska; Camilla Tøndel; Bojan Vujkovac; Frank Weidemann; Frits A Wijburg; Peter Woolfson; Carla E M Hollak
Journal:  Orphanet J Rare Dis       Date:  2015-03-27       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.